To evaluate the safety and effectiveness of the JenaValve Trilogy™ Heart Valve System for transcatheter aortic valve replacement (TAVR) in subjects with continuous flow left ventricular assist devices (cfLVAD) and clinically significant aortic regurgitation (AR) who are indicated for TAVR
Age range
18 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
Device Success
Timeframe: 30 days
Device Positioning
Timeframe: 30 days
Device Performance
Timeframe: 30 days
Surgery/intervention related to device
Timeframe: 30 days
Bleeding
Timeframe: 30 days
All Stroke
Timeframe: 30 days
Acute Kidney Injury
Timeframe: 30 days
Total aortic regurgitation
Timeframe: 30 days
Major Vascular Complication
Timeframe: 30 days
Permanent pacemaker implantation
Timeframe: 30 days
All-cause mortality
Timeframe: 30 days